These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 27022223)

  • 21. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
    Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral prophylaxis versus preemptive therapy to prevent cytomegalovirus infection and related death in liver transplantation: a retrospective study with propensity score matching.
    Kim SI; Kim CJ; Kim YJ; Son H; Kim YE; Kim MS; Hwang S; Kim JI; You YK; Kim DG; Kang MW
    Transplant Proc; 2012 Apr; 44(3):787-90. PubMed ID: 22483496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
    Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
    Müller V; Perrakis A; Meyer J; Förtsch T; Korn K; Croner RS; Yedibela S; Hohenberger W; Schellerer VS
    Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM; Lake KD; Arenas JD; Fontana RJ
    Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
    Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
    Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
    Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
    Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
    Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
    Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
    Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
    Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
    Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
    PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
    Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases.
    Nagai S; Mangus RS; Anderson E; Ekser B; Kubal CA; Fridell JA; Tector AJ
    Transplantation; 2016 Feb; 100(2):451-60. PubMed ID: 26247555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
    Jaksch P; Zweytick B; Kerschner H; Hoda AM; Keplinger M; Lang G; Aigner C; Klepetko W
    J Heart Lung Transplant; 2009 Jul; 28(7):670-5. PubMed ID: 19560694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
    Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.